EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Overview of aristolochic acid nephropathy: an update

Qingqing Zhou, Lei Jiang, Tao Su, Gang Liu, Li Yang

Kidney Research and Clinical Practice · 30.09.2023 · 42 (5) · 579-590

DOI: 10.23876/j.krcp.22.211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 30.09.2023. Verfasst von Qingqing Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Young Scientist Program, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aristolochic acid nephropathy (AAN) is a rapidly progressive renal interstitial fibrosis caused by medical or environmental exposure to aristolochic acid (AA). Since the outbreak of AAN in Belgium was reported nearly 30 years ago, the safety of herbal remedies has drawn considerable attention, and AAN has become a global public health problem. Breakthroughs have been made to better understand the disease, including the toxicity of AAs, the possible mechanisms of AAN, the disease patterns, and the pathological features; however, some critical problems remain unresolved. Because of the insidious onset of the disease, the incidence of AAN and the prevalence of exposure to AAs are unknown and might be largely underestimated. During the past decades, AA-containing herbs have been strictly administrated in many regions and the occurrence of AAN has declined sharply, yet cases of AAN are still sporadically reported. Despite the progress in the understanding of the disease’s pathogenesis, there is no effective treatment for delaying or reversing the renal deterioration caused by AAN. Therefore, the risk of exposure to AAs should be taken seriously by public health workers and clinicians. In this review, we updated the latest data on AAN, summarized the advances throughout these years, and put forward some challenges for future research.

Schlagwörter

Stichwörter der Autor:innen

Aristolochic acid nephropathyAristolochic acidsHerbal therapyInterstitial nephropathyRenal tubular dysfunction

Autor:innen und Institutionen

  • Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China.
  • Institute of Nephrology, Peking University, Beijing, China.
  • Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Beijing Young Scientist Program
  • CAMS Innovation Fund for Medical Sciences
  • PKU-Baidu Fund

Zitieren

APA

Zhou, Q., Jiang, L., Su, T., Liu, G., & Yang, L. (2023). Overview of aristolochic acid nephropathy: an update. Kidney Research and Clinical Practice, 42(5), 579-590. https://doi.org/10.23876/j.krcp.22.211

Vancouver

Zhou Q, Jiang L, Su T, Liu G, Yang L. Overview of aristolochic acid nephropathy: an update. Kidney Research and Clinical Practice. 2023;42(5):579-590. doi:10.23876/j.krcp.22.211

BibTeX
@article{Zhou2023,
  author = {Zhou, Qingqing and Jiang, Lei and Su, Tao and Liu, Gang and Yang, Li},
  title = {Overview of aristolochic acid nephropathy: an update},
  journal = {Kidney Research and Clinical Practice},
  year = {2023},
  volume = {42},
  number = {5},
  pages = {579--590},
  doi = {10.23876/j.krcp.22.211}
}
Kostenlos starten →